NCT06837948View on ClinicalTrials.gov

Neoadjuvant Chemotherapy Combined With Bispecific Antibody Versus Monoclonal Antibody in Locally Advanced NSCLC

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

February 18, 2025

Primary Completion Date

December 1, 2031

Study Completion Date

December 1, 2031

Conditions
Locally Advanced Non-Small Cell Lung Cancer
Interventions
DRUG

PM8002

Specified dose on specified days.

DRUG

Sintilimab

Specified dose on specified days.

DRUG

Nab-paclitaxel

Specified dose on specified days.

DRUG

Carboplatin

Specified dose on specified days.

PROCEDURE

Surgery

Patients with resectable tumor after neoadjuvant therapy will be treated with surgery.

Trial Locations (1)

200433

Shanghai Pulmonary Hospital, Shanghai

All Listed Sponsors
lead

Shanghai Pulmonary Hospital, Shanghai, China

OTHER